

**Retina Service Update Featuring the 13th Annual J. Arch McNamara, MD Memorial Lecture**

**Saturday, December 9, 2023**

**[Conference Description:](https://www.regeneron.com/%22%20Regeneron%22%20%22)**

[Click Here to Register for the Livestream](https://www.regeneron.com/%22%20Regeneron%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://www.regeneron.com/%22%20Regeneron%22%20%22)

[Thank you to our Exhibitors!](https://www.regeneron.com/%22%20Regeneron%22%20%22)

[Alcon
Allergan
Apellis
Bausch + Lomb
Coherus Biosciences
Genentech
Regeneron](https://www.regeneron.com/%22%20Regeneron%22%20%22)

**At the conclusion of the course, participants should be able to:**

1 Evaluate Avacincaptad vs. Pegtacoplan treatments for patients with GA

2 Collaborate with peers in preparation for surgical interventions involving areas of the eye outside of Retina & Vitreous

3 Speak with patients about complications and side effects of various retinal disease treatments including GA

4 Develop treatment plans for posterior segment complications from anterior segment surgery

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Live Activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Nothing to disclose - 03/02/2023 |
| James F. Vander, MD | Faculty | Nothing to disclose - 12/08/2023 |
| Rebecca R Soares, MD | Faculty | Nothing to disclose - 11/20/2023 |
| Meera Sivalingam, MD | Faculty, Planner | Nothing to disclose - 11/14/2023 |
| Jason Hsu, MD | Faculty | Consulting Fee-Iveric Bio|Consulting Fee-Gyroscope Therapeutics|Grant or research support-Genentech|Grant or research support-Iveric Bio|Grant or research support-Aldeyra Therapeutics (Relationship has ended) - 12/01/2023 |
| Carl D. Regillo, MD | Faculty | Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Regeneron|Consulting Fee-Astellas Pharma|Consulting Fee-Ocular Therapeutix|Consulting Fee-Zeiss|Consulting Fee-Sanofi (Relationship has ended)|Consulting Fee-Aderum Biotechnologies, Inc.|Consulting Fee-Alcon|Consulting Fee-Bausch + Lomb|Consulting Fee-Boehringer Ingelheim - 11/16/2023 |
| Yoshihiro Yonekawa, MD | Faculty | Paid consultant-Alcon|Advisor-Pykus|Paid consultant-EyePoint Pharmaceuticals (Relationship has ended) - 09/26/2023 |
| Jose Pulido, MD, MS, MPH, MBA | Faculty | Nothing to disclose - 12/05/2023 |
| Sunir J. Garg, MD | Faculty | Consulting Fee-Bausch + Lomb|Consulting Fee-Johnson & Johnson|Consulting Fee-Allergan|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Merck|Grant or research support-Allergan|Grant or research support-Boehringer Ingelheim|Grant or research support-Genentech|Grant or research support-Regeneron|Grant or research support-Apellis Pharmaceuticals|Grant or research support-NGM Bio - 05/31/2023 |
| Matt Starr, MD | Faculty | Advisor-Allergan|Advisor-REGENXBIO, Inc.|Advisor-Alimera Sciences|Advisor-Genentech|Consulting Fee-Gyroscope Therapeutics - 10/24/2023 |
| Anton Orlin, MD | Faculty, Planner | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended) - 04/24/2023 |
| Ethan C Heck, BM | Activity Coordinator | Nothing to disclose - 09/18/2023 |
| Michael N Cohen, MD | Faculty | Nothing to disclose - 11/18/2023 |
| Shaunna Lee, MD | Activity Coordinator | Nothing to disclose - 10/05/2023 |
| Michael Klufas, MD | Faculty | Consulting Fee-REGENXBIO, Inc.|Honoraria-Genentech|Honoraria-Regeneron|Honoraria-Coherus|Honoraria-Biogen|Consulting Fee-Abbvie|Grant or research support-Bausch + Lomb|Consulting Fee-Dutch Ophthalmic USA|Consulting Fee-Alimera Sciences - 11/14/2023 |
| Jordan Deaner, MD | Faculty | Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Alimera Sciences (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended) - 11/15/2023 |
| Sophie J Bakri, MD | Faculty | Consulting Fee-Abbvie|Consulting Fee-Adverum (Relationship has ended)|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Cholgene (Relationship has ended)|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-ilumen|Consulting Fee-Iveric Bio|Consulting Fee-Genentech|Consulting Fee-Neurotech|Consulting Fee-Novartis|Consulting Fee-Ocular Therapeutix|Consulting Fee-Outlook Therapeutics|Consulting Fee-Pixium|Stocks or stock options, excluding diversified mutual funds-Revana|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Rejuvitas (Relationship has ended)|Consulting Fee-Roche|Stocks or stock options, excluding diversified mutual funds-VoxelCloud|Consulting Fee-Zeiss (Relationship has ended)|Grant or research support-Lowy Medical Foundation (Relationship has ended)|Grant or research support-REGENXBIO, Inc. - 10/20/2023 |

